Abbott Laboratories on Monday agreed to pay $3.7 billion for Kos Pharmaceuticals Inc., in a move that will add two major cholesterol drugs to its product lineup. Kos specializes in lipid-management
products. It makes Niaspan, which helps raise "good" cholesterol levels, and Advicor, an advanced cholesterol treatment. "In speaking with Abbott, it is our sense that the company is excited to
expand its lipid franchise and is optimistic about the prospects for fixed-dose combination therapies," said Banc of America Securities analyst Glenn Novarro.
